Market Cap
$1.7B
OCUL
OCULAR THERAPEUTIX, INC
$7.05 ▼ -3.36%
Prev close $7.29Market cap$1.7B
ConsensusStrong Buy
12-mo target$27.09 (+284.5%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)30 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OCUL right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$1.2B
Inst. Activity
30 buys / 17 sells
Insider Activity
$461.4K buy / $2.4M sell
Insider Net $
-$2.0M
SEC Reports
11
Press Releases
3
Price chart 30d -35.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Sep 3, 2026 SEC Short Volume: OCUL — 56.5% short (3.9M / 6.9M)
Short: 3,875,588 | Exempt: 412,723 | TRF Vol: 6,859,672 | Short Ratio: 56.5% | Off-exchange volume (
Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief
CLUSTER — Impact 4/10
Aug 31, 2026 Insider
Aug 26, 2026 SEC Notman Donald sold 1,099 shares
Chief Operating Officer @ $10.24 ($11.3K)
Four OCUL insiders, including the Chief Scientific Officer and Chief Strategy Officer, sold a total of $322K in open-mar
CLUSTER — Impact 3/10
Aug 25, 2026 Insider
Dugel Pravin gifted 50,092 shares
See Remarks
Aug 24, 2026 Insider
Aug 3, 2026 SEC Kaiser Peter sold 3,035 shares
Chief Development Officer @ $10.77 ($32.7K)
Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share, which is a narrowe
8-K — Impact 7/10
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — TRIM
3,292,193 shares ($32.3M)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Sep 29, 2026 | Needham | REITERATE | Buy | 50% |
| Sep 16, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Sep 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 4, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Jun 25, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Jun 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 18, 2026 | Baird | MAINTAIN | Outperform | 54% |
| May 6, 2026 | RBC Capital | REITERATE | Outperform | 55% |
| May 5, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% |
Price targets
Where 11 covering analysts think OCUL trades over the next 12 months.
$27.09 +284.5% upside Strong Buy
Current$7.05 Low$18.00 Median$28.00 High$34.00 11 analysts
$18.00$34.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 2 bullish, 0 bearish, 3 mixed, 6 neutral · avg impact 4.6/10.Plus 3 press releases.
NEUTRALCLUSTER4/10
Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operatin
Sep 3, 2026
NEUTRALCLUSTER3/10
Four OCUL insiders, including the Chief Scientific Officer and Chief Strategy Officer, sold a total
Aug 26, 2026
BULLISH8-K7/10
Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share
Aug 3, 2026
BULLISHPRESS-RELEASE6/10
Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI in wet AMD in Q4 2026 based
Jun 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: OCUL — 56.5% short (3.9M / 6.9M)
Short: 3,875,588 | Exempt: 412,723 | TRF Vol: 6,859,672 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: OCUL — 60.8% short (0.3M / 0.6M)
Short: 335,258 | Exempt: 1,000 | TRF Vol: 551,405 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: OCUL — 58.7% short (0.5M / 0.8M)
Short: 458,086 | Exempt: 187 | TRF Vol: 780,266 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical
Sep 15, 2026
short_volume
Short Volume: OCUL — 58.6% short (0.5M / 0.9M)
Short: 517,887 | Exempt: 485 | TRF Vol: 883,844 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.35 | $-0.37–$-0.30 | 7.4% | +0.0% | 4↑ 0↓ | $0.0B | 5 |
| Next Q | $-0.38 | $-0.43–$-0.31 | -29.7% | +0.0% | 4↑ 0↓ | $0.0B | 5 |
| Current FY | $-1.43 | $-1.54–$-1.18 | -0.7% | +0.0% | 3↑ 0↓ | $0.1B | 4 |
| Next FY | $-1.45 | $-1.86–$-1.09 | -1.7% | +0.0% | 3↑ 1↓ | $0.1B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.352 | — |
| 7d ago | $-0.352 | — |
| 30d ago | $-0.352 | — |
| 60d ago | $-0.388 | +0.036 |
| 90d ago | $-0.388 | +0.036 |
Institutional ownership
Which big funds own OCUL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.2B total value (125,432,628 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, Avoro. Net buying activity: 30 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 32,844,043 | $322.5M | 26.2% | — |
| BlackRock, Inc. | 19,376,555 | $190.3M | 15.4% | — |
| Avoro Capital Advisors LLC | 12,540,000 | $123.1M | 10.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,832,595 | $86.7M | 7.0% | — |
| STATE STREET CORP | 5,233,282 | $51.4M | 4.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 5,021,092 | $49.3M | 4.0% | — |
| Point72 Asset Management, L.P. | 3,292,193 | $32.3M | 2.6% | TRIM -40.5% |
| DIMENSIONAL FUND ADVISORS LP | 2,783,367 | $27.3M | 2.2% | DOUBLED +328.4% |
| BALYASNY ASSET MANAGEMENT L.P. | 2,270,707 | $22.3M | 1.8% | DOUBLED +252.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,973,130 | $19.4M | 1.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | TRIM | 5,534,985 | 3,292,193 | -40.5% | $32.3M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 649,756 | 2,783,367 | +328.4% | $27.3M |
| GOLDMAN SACHS GROUP INC | ADD | 1,110,366 | 1,761,754 | +58.7% | $17.3M |
| Nuveen, LLC | DOUBLED | 411,080 | 1,697,274 | +312.9% | $16.7M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,550,000 | — | $15.2M |
| Squarepoint Ops LLC | ADD | 980,757 | 1,415,913 | +44.4% | $13.9M |
| MORGAN STANLEY | TRIM | 1,280,119 | 911,831 | -28.8% | $9.0M |
| Man Group plc | DOUBLED | 177,468 | 543,582 | +206.3% | $5.3M |
| BANK OF AMERICA CORP /DE/ | ADD | 397,092 | 519,231 | +30.8% | $5.1M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 150,744 | 484,120 | +221.2% | $4.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 40 transactions. Net -$2.0M — $461.4K bought, $2.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Notman Donald | Chief Operating Officer | SELL | 1,099 | $10.24 | $11.3K |
| Aug 25, 2026 | Dugel Pravin | See Remarks | GIFT | 50,092 | — | — |
| Aug 24, 2026 | Kaiser Peter | Chief Development Officer | SELL | 3,035 | $10.77 | $32.7K |
| Aug 24, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 1,897 | $10.78 | $20.4K |
| Aug 24, 2026 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3,296 | $10.78 | $35.5K |
| Aug 24, 2026 | Dugel Pravin | See Remarks | SELL | 21,649 | $10.77 | $233.2K |
| Jun 16, 2026 | Dugel Pravin | See Remarks | GIFT | 50,092 | — | — |
| Jun 10, 2026 | Williams Leslie J. | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Williams Leslie J. | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | RAINES MERILEE | Director | AWARD | 14,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OCUL.
Shares short
29,933,140
Settlement Sep 15, 2026
Change vs prior
+6.7%
Semi-monthly cycle
Days to cover
14.2
At avg daily volume
Of shares outstanding
≈13.6%
Estimate — not % of float
All OCUL filing & press-release reports (14)
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 26, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportJun 17, 2026
- 8-K reportJun 12, 2026
- PRESS-RELEASE reportJun 4, 2026
- CLUSTER reportMay 28, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportApr 1, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 26, 2026